A Phase 3, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/GS-5816 Fixed Dose Combination for 12 Weeks in Subjects With Chronic HCV
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 14 Aug 2017
At a glance
- Drugs Sofosbuvir/velpatasvir (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors Gilead Sciences
- 09 Aug 2017 Status changed from recruiting to active, no longer recruiting.
- 12 Sep 2016 Planned End Date changed from 1 Dec 2017 to 1 Apr 2018.
- 12 Sep 2016 Planned primary completion date changed from 1 Sep 2017 to 1 Jan 2018.